68 Ga-NOTA-m-SNA006: A Next-Generation CD8-Targeting Nanobody Probe to Enhance Renal and Hepatic Clearance in Noninvasive ImmunoPET Imaging

作者：Tukang Peng, Chao Wang, Jun Wen, Qingyu Zhang, Cheng Wang, Chun Lv, Fuqiang Du, Zhoumi Hu, Tao Xu, Gang Huang, Jianjun Liu, Haitao Zhao · 发表于：Molecular Pharmaceutics · 年份：2025 · DOI：10.1021/acs.molpharmaceut.5c00041 · 被引用次数：6 · 研究领域：Advanced biosensing and bioanalysis techniques、Extracellular vesicles in disease、Nanoplatforms for cancer theranostics

The 68 Ga-labeled nanobody SNA006 marks a significant advancement in noninvasive immunoPET imaging of CD8 + T cells, facilitating real-time tracking of cellular immune responses in cancer, yet its pharmacokinetic properties remain suboptimal. This study aimed to develop a next-generation CD8-targeting immunoPET nanobody probe by incorporating a PEGylated brush border membrane enzyme-cleavable linker to improve pharmacokinetics and to evaluate its characterization in CD8-positive intrapulmonary tumors. A precursor based on SNA006, containing a PEGylated brush border membrane enzyme-cleavable linker, was designed, synthesized, and radiolabeled with gallium-68 to yield 68 Ga-NOTA-m-SNA006. The probe was subsequently assessed both in vitro and in vivo. The probe exhibited high radiochemical yield, purity, and favorable stability, and demonstrated binding to the CD8 protein with high affinity. PET/CT imaging and biodistribution studies revealed that 68 Ga-NOTA-m-SNA006 exhibited favorable pharmacokinetic properties, including rapid clearance from the kidneys, reduced liver uptake, and sustained retention in the tumor, compared with 68 Ga-NODAGA-SNA006. 68 Ga-NOTA-m-SNA006 exhibited high uptake in lung lesions during in vivo PET imaging, reflecting CD8 expression in an intrapulmonary tumor model. In summary, we present a novel 68 Ga-labeled SNA006 radiotracer with an optimized linker moiety, 68 Ga-NOTA-m-SNA006, which effectively decreases renal and hepatic uptake while maintaining...